Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics - Wikidata - thesis-toulmin - TriplyDB

Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics

Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics

http://www.wikidata.org/entity/Q27004000

about

Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic Events Physiology of natriuretic peptides: The volume overload hypothesis revisited Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data.Innovative Therapeutics: Designer Natriuretic Peptides.Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides.Renal Mechanisms of Association between Fibroblast Growth Factor 1 and Blood Pressure.Computerized tomography measured liver fat is associated with low levels of N-terminal pro-brain natriuretic protein (NT-proBNP). Multi-Ethnic Study of Atherosclerosis Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life?Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.Development and Validation of Risk Prediction Models for Cardiovascular Events in Black Adults: The Jackson Heart Study Cohort.Beneficial Effects of Combined AT1 Receptor/Neprilysin Inhibition (ARNI) Versus AT1 Receptor Blockade Alone in the Diabetic Eye.The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment.Natriuretic peptides in cardiovascular diseases: current use and perspectives Neprilysin inhibition in chronic kidney disease Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure.The basis of translational physiology: from molecules to humans, a wide arc of scientific inquiry.LCZ696: the next step in improving RAS inhibition?Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy.Dobutamine Therapy is Associated with Worse Clinical Outcomes Compared with Nesiritide Therapy for Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.Unraveling the mechanisms of action of lactoferrin-derived antihypertensive peptides: ACE inhibition and beyond.Cardiac Physiology of Aging: Extracellular Considerations.An update of the blockade of the renin angiotensin aldosterone system in clinical practice.New medical therapies for heart failure.New and old agents in the management of diabetic nephropathy.Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development.Neprilysin and Natriuretic Peptide Regulation in Heart Failure.Resetting the neurohormonal balance in heart failure (HF): the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF Calibrating the impact of dual RAAS blockade on the heart and the kidney - balancing risks and benefits.Focus on the Novel Cardiovascular Drug LZC696: from Evidence to Clinical Consideration.Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure.Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care?Substance P promotes wound healing in diabetes by modulating inflammation and macrophage phenotype.The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan.Is natriuretic peptide receptor C a new target for hypertension therapeutics?The Role of Neprilysin Inhibitors in Cardiovascular Disease.

P2860

Q26778333-61AA0253-FE6F-414F-B0EA-F1CDCCDB2CB3 Q26851856-5DF9BC57-B254-4F17-9B48-73D52A8F1977 Q28088583-CA272378-9AFF-4227-86AD-62C45E95E877 Q31131772-0D716112-E41C-4A13-9E04-566667FF2925 Q33653332-F04A221C-FEA4-4035-B672-DD5A4E9FB748 Q35035016-4D06F2F9-72F4-4D68-B429-DD7069C21421 Q35407690-A011BDAE-EF95-461B-AA97-6618C5143944 Q36054705-18789C16-AE77-47C9-A2E0-C23CB9D88158 Q36314969-A6367177-5A7C-441F-A365-36895F669D8A Q36806485-29488F38-4FCC-4AE9-88E3-D34072F8D5B3 Q37292234-302D5CE1-859B-4375-BBA7-41C0375ADA91 Q37412804-760AB40F-0ECB-47C6-9072-697B120EF9F1 Q37423205-0EF857E6-33F9-4FC6-9576-2721B9D2231B Q37503374-D321CD79-B2CB-418D-869C-CC42B9989EFF Q37583865-62684EA2-E54A-4951-9638-8F3FD494CF6A Q38162429-AC7AE517-2071-4B90-8721-0E6A92885CA1 Q38241522-9BBF5B9A-5B91-48C1-9B14-0FD1D4B85AF4 Q38248810-93EEFD72-BBB0-493C-9263-B5E2A2F00901 Q38307438-C5ABD2E3-839F-4D2C-8DB1-23CB1B0AC383 Q38400734-E0EAFEB8-0F19-4862-B94B-927639339FAF Q38534772-0AC6BE7E-AB4F-4502-B0DF-890F5DB4A6F5 Q38540286-5C5BCA56-E585-43ED-AE73-2F47844199BE Q38541114-A0147C28-0B29-440B-92C8-209F534C37B5 Q38542448-7C44E1D3-1335-4DF5-B07E-337E4FDAD54E Q38590227-7204B91C-BA3A-47BE-9739-190A25F8E960 Q38594785-33CFA5B5-499B-47B0-A7CC-E34C407ACBC2 Q38738871-4CDA4D28-AD3F-44FB-A178-2F6BEEFCD442 Q38780567-E8C47DCD-5A8A-496D-8A92-10D013A5481B Q38790076-E65F4E57-C63D-446B-8436-50C8A460F669 Q38853482-1A4C5C41-900E-48DC-8FF2-9271FA5833AC Q38854043-18DADF7B-E286-4678-9255-AF28BAADF749 Q38859432-33F92EA2-3DF2-42C7-9CC2-40589A85BEC7 Q39011741-CE6A0E04-34E2-43E4-B936-2F48F770AFD3 Q39247505-B9B7E0A7-6D67-4E8D-B608-874E1857D82D Q40000430-CD847CF7-8DF4-432E-AC09-78440E7002DE Q40116429-159E930B-2402-4245-AE32-040775DBD79F Q41464720-17F558BD-15E4-4C4C-A910-ACE7670481E5 Q41549636-7D49FA62-681E-43C5-AC4E-8840D7F4E5DA Q42394649-74E14030-CB8E-4BD5-ACBB-04FDB6FD06F9 Q42700358-CB0E2E77-7415-4515-B91B-0AAAEFF01C66

P2860

Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics

http://www.wikidata.org/entity/Q27004000

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Neutral endopeptidase inhibiti ...... in cardiovascular therapeutics

@ast

Neutral endopeptidase inhibiti ...... in cardiovascular therapeutics

@en

Neutral endopeptidase inhibiti ...... in cardiovascular therapeutics

@nl

type

label

Neutral endopeptidase inhibiti ...... in cardiovascular therapeutics

@ast

Neutral endopeptidase inhibiti ...... in cardiovascular therapeutics

@en

Neutral endopeptidase inhibiti ...... in cardiovascular therapeutics

@nl

prefLabel

Neutral endopeptidase inhibiti ...... in cardiovascular therapeutics

@ast

Neutral endopeptidase inhibiti ...... in cardiovascular therapeutics

@en

Neutral endopeptidase inhibiti ...... in cardiovascular therapeutics

@nl

P1433

Q27004000-8E537599-8E72-48C4-A840-9A399D471935

P1476

Q27004000-35090E17-EADB-44B5-BEF7-6F6C2660E5C5

P2093

Q27004000-0291D81C-6FC5-4C82-A4E4-C9FB86106D0F

Q27004000-6D23C6AF-7574-4E65-8821-67961F755C4C

Q27004000-8D914E0F-04D9-45B9-AE98-1E0A83463809

Q27004000-AF235095-DD46-459C-A814-A4B510A8706B

Q27004000-B3FDFA40-7D3E-42B5-90CA-69D0FE9FF76F

P2860

Q27004000-00C77828-EABC-45DC-B874-7ACBA29C3506

Q27004000-08327CF4-128C-4FE0-ACAE-4A0B3755CCB5

Q27004000-0AD67E9E-2E60-496F-AB5A-A88763237891

Q27004000-137F6D10-60BD-428C-B0F1-908450AD361C

Q27004000-17B9A1D1-317F-4DF2-A6B2-D9AF09B29367

Q27004000-1882B3DB-BD6B-4FD6-BE1C-145A9769693B

Q27004000-1E211279-4217-4727-8143-C7BA3D3E14CB

Q27004000-2208D225-42C1-42B3-9156-105233B5B714

Q27004000-23147027-7405-4D53-A5E1-C8521F7E1CB2

Q27004000-28D6703D-7DC9-427A-9045-4082D844F882

P304

Q27004000-5FBF0962-2052-4CD0-827C-5AF53FBB43EE

P31

Q27004000-136A7BF3-7E36-4395-B776-361FBDD31585

P356

Q27004000-EFA71A15-020A-4FC9-A911-C547DDE0627C

P407

Q27004000-1EB96527-1EA1-4FBB-A707-1AA55D8B0DCA

P433

Q27004000-F2131E10-30C2-44C1-9E3A-F193042C4860

P478

Q27004000-67B67FE4-9A45-441B-93C7-06297E17CE73

P577

Q27004000-901A4EF3-9935-414D-9A35-3A7F3CA9D16F

P5875

Q27004000-C26A1484-C6EB-4C03-830E-6D2FE26613F4

P698

Q27004000-B493AC04-1888-43AA-8BCD-F0D7EA32D407

P921

Q27004000-7F2F3261-1557-467F-9233-47EDEB8A8D02

P932

Q27004000-89E813F2-DD56-49E9-AFF0-C7BF2C064B19

P356

P1433

European Heart Journal

P1476

Neutral endopeptidase inhibiti ...... in cardiovascular therapeutics

@en

P2093

A. Cataliotti

http://www.w3.org/2001/XMLSchema#string

I. A. Andersen

http://www.w3.org/2001/XMLSchema#string

J. C. Burnett

http://www.w3.org/2001/XMLSchema#string

L. C. Costello-Boerrigter

http://www.w3.org/2001/XMLSchema#string

S. Mangiafico

http://www.w3.org/2001/XMLSchema#string

P2860

Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11

Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk

CNP production in the kidney and effects of protein intake restriction in nephrotic syndrome

Effect of nesiritide in patients with acute decompensated heart failure

Comparison of the hydrolysis of the three types of natriuretic peptides by human kidney neutral endopeptidase 24.11

Natriuretic peptide receptor-C signaling and regulation

Hypertension in mice lacking the proatrial natriuretic peptide convertase corin

Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum

Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension.

Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth.

P304

886-893c

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHS262

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230784202

http://www.w3.org/2001/XMLSchema#string

P698

22942338

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

3604644

http://www.w3.org/2001/XMLSchema#string